MetaboLights

application/xml

ftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14123/m_MTBLS14123_LC-MS_positive_reverse-phase_metabolite_profiling_v2_maf.tsvftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14123/m_MTBLS14123_LC-MS_negative_reverse-phase_metabolite_profiling_v2_maf.tsvftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14123/s_MTBLS14123.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14123/a_MTBLS14123_LC-MS_positive_reverse-phase_metabolite_profiling.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14123/i_Investigation.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14123/a_MTBLS14123_LC-MS_negative_reverse-phase_metabolite_profiling.txtprimaryOK200ftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14123fecesmass spectrometry assayThe identified metabolites were annotated using the KEGG database (https://www.genome.jp/kegg/pathway.html), the HMDB database (https://hmdb.ca/metabolites), and the LIPID Maps database (http://www.lipidmaps.org/).Tissues (100 mg) were individually grounded with liquid nitrogen and the homogenate was resuspended with prechilled 80% methanol by well vortex. The samples were incubated on ice for 5 min and then were centrifuged at 15,000 g, 4°Cfor 20 min. Some of supernatant was diluted to final concentration containing 53%methanol by LC-MS grade water. The samples were subsequently transferred to a fresh Eppendorf tube and then were centrifuged at 15000 g, 4°C for 20 min. Finally, the supernatant was injected into the LC-MS/MS system analysisHomo sapiensThe raw data (.raw) files were imported into Compound Discoverer 3.3 (CD 3.3) software for processing. Initially, a simple screening of parameters, including retention time and mass-to-charge ratio (m/z), was performed for each metabolite. The first Quality Control (QC1) sample was then used for peak area correction to improve identification accuracy. Subsequently, peak extraction was conducted by setting parameters such as a mass tolerance of 5 ppm, a signal intensity tolerance of 30%, minimum signal intensity, and adduct ions. Simultaneously, peak areas were quantified and target ions were integrated. Following this, molecular formulas were predicted based on molecular ion peaks and fragment ions, and the results were aligned with the mzCloud (https://www.mzcloud.org/), mzVault, and Masslist databases. Background ions were filtered out using blank samples. The raw quantitative data were then standardized to obtain relative peak areas using the following formula: raw quantitative value of the sample / (sum of metabolite quantitative values in the sample / sum of metabolite quantitative values in the QC1 sample). Compounds with a coefficient of variation (CV) for relative peak areas exceeding 30% across QC samples were removed, ultimately yielding the final metabolite identification and relative quantification results. The data processing phase was executed on a Linux operating system (CentOS version 6.6) using R and Python software.Groupzhf15924@163.comhttps://www.ebi.ac.uk/metabolights/MTBLS14123Baseline fecal samples were collected at the study's onset prior to any intervention. Subjects were administered the assigned probiotic treatment prior to their initial 12-hour phototherapy session. Immediately following this 12-hour treatment period, clinical parameters were recorded, and a subsequent stool sample was collected. After a 6- to 8-hour resting interval, this standardized cycle of treatment, clinical assessment, and sample collection was repeated on the second and third days. If clinically indicated, subjects underwent a fourth and fifth 12-hour phototherapy session following the identical procedure. Sampling concluded upon the cessation of phototherapy and the subsequent discharge of the subjects.MetaboLightsPublicMetabolomicsLiquid Chromatography MS - negative - reverse-phaseLiquid Chromatography MS - positive - reverse-phaseProbioticsBilirubinneonatal jaundiceuntargeted metabolite profilingUHPLC separation was performed using a Vanquish UHPLC system (Thermo Fisher Scientific, Germany) equipped with a Hypersil Gold column (100 x 2.1 mm, 1.9 μm). The flow rate was maintained at 0.2 mL/min.Mobile Phases:Positive polarity mode: Eluent A (0.1% Formic Acid in water) and Eluent B (Methanol).Negative polarity mode: Eluent A (5 mM ammonium acetate, pH 9.0) and Eluent B (Methanol).Solvent Gradient: The elution gradient was set as follows: 2% B at 1.5 min; 2-85% B at 3 min; 85-100% B at 10 min; 100-2% B at 10.1 min; and maintained at 2% B until 12 min.The enhancing therapeutic effect of neonatal jaundice by bifidobacterium through regulating inflammation and gut microbiota in combination with phototherapy:A randomized controlled trail.The enhancing therapeutic effect of neonatal jaundice by bifidobacterium through regulating inflammation and gut microbiota in combination with phototherapy—a randomized controlled trial.ProbioticsBilirubinuntargeted metabolite profilingneonatal jaundiceFeng ZhangShanghai Ocean UniversityMass spectrometry analysis was conducted using an Orbitrap Q Exactive HF or Orbitrap Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific, Germany). The instrument was operated in both positive and negative polarity modes with the following parameters:Spray voltage: 3.5 kV;Capillary temperature: 320°C;Sheath gas flow rate: 35 psi;Auxiliary gas flow rate: 10 L/min;Auxiliary gas heater temperature: 350°C;S-lens RF level: 60 falseThe enhancing therapeutic effect of neonatal jaundice by bifidobacterium through regulating inflammation and gut microbiota in combination with phototherapy—a randomized controlled trialHyperbilirubinemia is one of the most common diseases in neonates, and phototherapy is currently the most commonly used treatment in medicine, but previous studies have found that phototherapy can lead to changes in the intestinal flora of jaundice neonates, especially bifidobacteria. The focus of this study is whether the precise addition of bifidobacteria can alleviate the intestinal microbiota disorder caused by phototherapy and improve the clinical outcomes of jaundice neonates. In this study, two strains of Bifidobacterium derived from healthy infants were added to jaundice neonates receiving phototherapy, and the effects of probiotics on the improvement of clinical symptoms, intestinal microbiota structure and metabolic indexes, and intestinal inflammatory factors in jaundice neonates during phototherapy were investigated. For neonates receiving phototherapy, the addition of M-16V+Bb-12 probiotics can improve the diversity of microflora, reduce the fixed value of harmful bacteria in the intestine, and enhance the excretion of bilirubin from the intestine, so as to improve the inflammatory damage and microbiota disorder caused by phototherapy, and achieve the effect of clinically improving jaundice, reducing bilirubin, shortening the length of hospitalization, and promoting neurodevelopment. It provides a safer and more effective treatment for neonatal jaundice.2026-03-262026-03-24MTBLS14123